Skip to main content

Table 1 Baseline characteristics by treatment group

From: Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes

Parameter

ERN/LRPT

  

Placebo

  

(N = 393)

(N = 323)

Overall Population

Baseline TG subgroup

Overall Population

Baseline TG subgroup

  

<2.26 mmol/L (n = 320)

≥2.26 mmol/L (n = 73)

 

<2.26 mmol/L (n = 279)

≥2.26 mmol/L (n = 44)

Age, mean ± SD, y

61.80 ± 9.29

62.08 ± 9.27

60.58 ± 9.36

61.77 ± 9.43

62.04 ± 9.33

60.09 ± 9.99

Age, median (range), y

63 (31–79)

63 (33–79)

61 (31–76)

63 (21–80)

63 (21–80)

63 (36–77)

Sex, no. (%)

      

 Male

233 (59.3)

187 (58.4)

46 (63.0)

208 (64.4)

182 (65.2)

26 (59.1)

 Female

160 (40.7)

133 (41.6)

27 (37.0)

115 (35.6)

97 (34.8)

18 (40.9)

Population subgroups, no. (%)a

      

 Statin-treated

310 (78.9)

259 (80.9)

51 (69.9)

259 (80.2)

227 (81.4)

32 (72.7)

 Other LMT-treated

33 (8.4)

24 (7.5)

9 (12.3)

34 (10.5)

28 (10.0)

6 (13.6)

 Drug naive

72 (18.3)

54 (16.9)

18 (24.7)

55 (17.0)

47 (16.8)

8 (18.2)

BMI, mean ± SD, kg/m2

31.28 ± 6.45

30.90 ± 6.43

32.93 ± 6.34

30.48 ± 5.83

30.26 ± 5.92

31.84 ± 5.01

Baseline values, mean ± SD

      

 apoB, g/L

0.93 ± 0.19

0.90 ± 0.17

1.1 ± 0.18

0.91 ± 0.17

0.89 ± 0.15

1.1 ± 0.20

 TC, mmol/L

4.30 ± 0.68

4.20 ± 0.67

4.69 ± 0.58

4.21 ± 0.64

4.14 ± 0.60

4.65 ± 0.75

 Non-HDL-C, mmol/L

3.00 ± 0.64

2.85 ± 0.57

3.64 ± 0.54

2.91 ± 0.58

2.81 ± 0.50

3.53 ± 0.64

 HDL-C, mmol/L

1.29 ± 0.36

1.35 ± 0.35

1.04 ± 0.25

1.30 ± 0.34

1.33 ± 0.35

1.12 ± 0.25

 LDL-C, mmol/L

2.26 ± 0.53

2.26 ± 0.53

2.27 ± 0.55

2.20 ± 0.47

2.19 ± 0.44

2.27 ± 0.61

 TGb, mmol/L

1.42 (0.36–7.10)

1.27 (0.36–2.23)

2.88 (2.28–7.10)

1.45 (0.44–5.75)

1.32 (0.44–2.24)

2.63(2.26–5.75)

 CRPb, mg/L

1.8 (0.1–56.2)

1.7 (0.1–56.2)

2.3 (0.3–36.3)

1.5 (0.1–69.7)

1.5 (0.1–69.7)

1.40 (0.3–15.7)

 FPG, mmol/L

7.29 ± 1.81

7.10 ± 1.63

8.11 ± 2.28

7.41 ± 1.79

7.38 ± 1.83

7.62 ± 1.59

 HbA1c, %

6.91 ± 0.72

6.86 ± 0.69

7.11 ± 0.81

6.90 ± 0.70

6.89 ± 0.69

6.97 ± 0.74

  1. ApoB apolipoprotein B; BMI body mass index; ERN/LRPT ER niacin/laropiprant; HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol; TC total cholesterol; TG triglyceride; CRP C-reactive protein; FPG fasting plasma glucose; HbA1c hemoglobin A1c
  2. aBecause a patient can be taking both a statin and another LMT at baseline, the total percentage may be greater than 100 %
  3. bExpressed as median
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X